Schoen M D, Parker R B, Hoon T J, Hariman R J, Bauman J L, Beckman K J
Department of Pharmacy Practice, University of Illinois, Chicago 60612.
Am J Cardiol. 1991 Feb 1;67(4):300-4. doi: 10.1016/0002-9149(91)90563-z.
To evaluate the effects of calcium pretreatment on the disposition and electrocardiographic effects of verapamil, 8 healthy male volunteers received treatment in each of 3 phases in a randomized, double-blind, crossover manner. Phase I denoted 10 ml of 0.9% intravenous sodium chloride followed by 10 mg of intravenous verapamil; phase II denoted 10 ml of 10% intravenous calcium chloride followed by 4 ml of 0.9% intravenous sodium chloride; and phase III denoted 10 ml of 10% intravenous calcium chloride followed by 10 mg of intravenous verapamil. Blood samples for the determination of verapamil concentrations were drawn at 5, 10, 15, 20, 30, 45, 60 and 90 minutes, and at 2, 4, 6, 10 and 24 hours. Blood pressure, heart rate and PR intervals were also measured at these times. Pretreatment of verapamil with intravenous calcium did not alter the disposition of intravenous verapamil. Blood pressure was not significantly altered in any treatment phase, although calcium tended to increase mean arterial pressure and verapamil abolished this effect. Calcium had no significant affect on verapamil-induced PR prolongation (maximum percent change in PR interval: phase I = 19 +/- 11%, phase III = 18 +/- 7%; time to maximal prolongation: phase I = 0.38 +/- 0.21 hours, phase III = 0.37 +/- 0.26 hours; and area under the percent change in PR vs time curve: phase I = 15.5 +/- 10, phase III = 21 +/- 9). Verapamil caused a reflex increase in heart rate of similar magnitude in both phases I and III (24 +/- 10% and 21 +/- 7%, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
为评估钙预处理对维拉帕米的处置及心电图效应的影响,8名健康男性志愿者按随机、双盲、交叉方式在3个阶段分别接受治疗。第一阶段为静脉注射10ml 0.9%氯化钠溶液,随后静脉注射10mg维拉帕米;第二阶段为静脉注射10ml 10%氯化钙溶液,随后静脉注射4ml 0.9%氯化钠溶液;第三阶段为静脉注射10ml 10%氯化钙溶液,随后静脉注射10mg维拉帕米。在5、10、15、20、30、45、60和90分钟以及2、4、6、10和24小时采集血样以测定维拉帕米浓度。在这些时间点还测量血压、心率和PR间期。静脉注射钙预处理维拉帕米未改变静脉注射维拉帕米的处置。尽管钙倾向于升高平均动脉压,且维拉帕米消除了这种效应,但在任何治疗阶段血压均未显著改变。钙对维拉帕米引起的PR间期延长无显著影响(PR间期最大变化百分比:第一阶段=19±11%,第三阶段=18±7%;达到最大延长时间:第一阶段=0.38±0.21小时,第三阶段=0.37±0.26小时;PR间期变化百分比与时间曲线下面积:第一阶段=15.5±10,第三阶段=21±9)。在第一阶段和第三阶段,维拉帕米引起的心率反射性增加幅度相似(分别为24±10%和21±7%)。(摘要截短于250字)